FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D C 20540	

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours not recognise	0.5							

_	Check this box if no longer subject to Section 16.
- 1	Form 4 or Form 5 obligations may continue. See
_	Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Name and Address of Reporting Person*     Garella Rahul  (Last) (First) (Middle)  C/O ENDO INTERNATIONAL PLC FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD					Issuer Name and Ticker or Trading Symbol     Endo International plc [ ENDP ]  3. Date of Earliest Transaction (Month/Day/Year) 04/02/2020									all applicab Directo	iship of Reporting Person(s) to Issuer applicable)  Director 10% Owner  Officer (give title below) Other (specify below)  EVP, Intl Pharmaceuticals					
(Street) BALLSBRIDGE, DUBLIN  (City) (State) (Zip)				4	4. If Amendment, Date of Original Filed (Month/Day/Year)								- 1	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
D			Date	Date (Month/Day/Year) i		Execution Date,		3. Transaction Code (Instr. 8) 4. Securit (D) (Instr.		ties Acqui 3, 4 and 5	red (A) or D 5)	isposed Of	Beneficia	ficially Owned [		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial		
["									v	Amount (A) or (D) Price		Price		Transaction(s) (In				Ownership (Instr. 4)		
Ordinary Shares			04/0	2/2020(1)	(1)		F		9,329 <sup>(2)</sup> D		\$3.09(3)	5	50,991		D					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
Security (Instr. 3) Conversion or Exercise Price of Derivative (Month/Day/Year) if any (Month/D		3A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Se Underlying Derivative Sec 3 and 4)			str. Deriva	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned	e G s ally (	10. Ownership Form: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
Evnlanation of Desnonses	Security  Code V (A) (D) Date Expiration Date Title					Amount of Number of Shares			Following Reported Transaction(s) (Instr. 4)		Instr. 4)									

- 1. Thirty-three and one-third percent (33 1/3%) of Mr. Garella's April 2, 2018 grant of restricted stock units (RSUs) vested on April 2, 2020.

  2. These shares represent stock withheld by Endo International plc to satisfy Mr. Garella's tax withholding obligations on shares acquired upon vesting of RSUs.

  3. Represents the vesting price which is the closing share price on April 2, 2020.

## Remarks:

/s/ Yoon Ah Oh, by power of attorney 04/06/2020

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. 
† If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these present that the undersigned hereby makes, constitutes and appoints Matthew J. Maletta, Yoon Ah Oh, Carrie A. Nichol, Ju:

- (1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of I
- (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's secur:
- (3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned acknowledges that:
- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such
- (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be
- (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the require
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing to This Power of Attorney shall remain in full force and effect with respect to each undersigned until revoked by such undersigned in a signer

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1 day of August 2019.

SIGNATURE TITLE

/S/ RAHUL GARELLA Executive Vice President, International Pharmaceuticals

NAME: Rahul Garella

STATE OF Dublin, Ireland: COUNTY OF Dublin, Ireland:

On this 1 day of August 2019, the above-named individual personally appeared before me, and acknowledged that he executed the foregoing instru IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

/S/ JAMES JONES Notary Public